To further investigate the relationship between MitoScore and clinicopathological parameters, which validate the predictive ability of MitoScore on GC prognosis, we conducted a stratified analysis based on the expression of the 12 genes in relation to TNM stage, age, gender, tumor level, clinical molecular subtype, Her2 positivity, PI3CA mutation status, TP53 mutation status, and EGFR mutant status. This evidence concerns the gene TP53 and gastric cancer.